Core Laboratories (CLB) AI Stock Analysis

• Market Cap: $573.38M
• Dividend Yield: 0.33%
• Average Volume (3M): 517.00K
• Price to Earnings (P/E): 20.5
• Beta (1Y): 0.85
• Revenue Growth: 1.32%
• EPS Growth: -33.17%
• Country: US
• Employees: 3,400
• Sector: Energy
• Sector Strength: 53
• Industry: Oil & Gas Equipment & Services
• EPS (TTM): 0.14
• Shares Outstanding: 46,882,935
• 10 Day Avg. Volume: 757,166
• 30 Day Avg. Volume: 517,001
• PEG Ratio: -2.74
• Price to Book (P/B): 4.97
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 63.72
• Enterprise Value/Market Cap: 2.00
• Enterprise Value/Revenue: 0.55
• Enterprise Value/Gross Profit: 13.09
• Enterprise Value/Ebitda: 4.14
• 1Y Price Target: $13.00
• Price Target Upside: 1.72% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 2

• Rating: 66 Neutral
• Price Target: $13.00 ▲(1.72%Upside)

Core Laboratories' overall score is influenced primarily by its solid financial performance and strategic operational improvements despite geopolitical challenges impacting immediate results. The technical analysis indicates a neutral market stance, and valuation metrics suggest a slightly overvalued position. The recent earnings call provides a mixed outlook with both strengths and challenges.

Positive Factors

Geopolitical Developments

Potential easing of geopolitical tensions between Russia and Ukraine could serve as a positive catalyst for the company.

Research and Development

The Research and Development division is expected to grow, likely outpacing international upstream capital expenditure growth.

Stock Upgrade

The stock has been upgraded to Neutral, reflecting a more balanced risk/reward scenario.

Negative Factors

Operational Challenges

Production Enhancement has shrunk to just 11% of total company operating income, indicating challenges in that segment.

Core Laboratories Business Overview & Revenue Model

Company Description

Core Laboratories N.V. provides reservoir description and production enhancement services and products to the oil and gas industry in the United States, Canada, and internationally. It operates through Reservoir Description and Production Enhancement segments. The Reservoir Description segment includes the characterization of petroleum reservoir rock, reservoir fluid, and gas samples to enhance production and improve recovery of oil and gas from its clients' reservoirs. It offers laboratory-based analytical and field services to characterize properties of crude oil and oil delivered products; and proprietary and joint industry studies. The Production Enhancement segment provides services and products relating to reservoir well completions, perforations, stimulations, and production. It offers integrated diagnostic services to evaluate and monitor the effectiveness of well completions and to develop solutions to improve the effectiveness of enhanced oil recovery projects. In addition, the company markets and sells its products through a combination of sales representatives, technical seminars, trade shows, and print advertising, as well as through distributors. It operates approximately in 50 countries. The company was founded in 1936 and is based in Amstelveen, the Netherlands.

How the Company Makes Money

Core Laboratories generates revenue primarily through its two main business segments: Reservoir Description and Production Enhancement. The Reservoir Description segment provides laboratory-based analytical and field services to characterize and evaluate the properties of oil and gas reservoirs. This includes services such as core and fluid analysis, which are critical for understanding reservoir conditions and maximizing resource extraction. The Production Enhancement segment focuses on providing technologies and services that improve the efficiency and output of oil and gas wells. This includes services like hydraulic fracturing diagnostics and well perforation. Core Laboratories also benefits from long-term contracts and strategic partnerships with major oil companies, which ensure a steady revenue stream. The company's emphasis on proprietary technologies and innovation is a significant factor in maintaining its competitive edge and driving its earnings.

Core Laboratories Financial Statement Overview

Summary

Core Laboratories exhibits solid profitability and cash flow metrics, which are crucial for sustained operations in the volatile oil & gas equipment and services industry. Despite leverage concerns flagged by a moderate balance sheet, the company maintains a stable financial position with effective cash flow management and profitability. Future growth will depend on maintaining revenue stability and careful debt management.

Income Statement

Core Laboratories shows solid profitability with a gross profit margin of 36.8% and a net profit margin of 5.4% for TTM. The revenue growth has been stable, with a slight decline recently, but overall EBIT and EBITDA margins remain healthy, indicating efficient operations.

Balance Sheet

The company has a moderate debt-to-equity ratio of 0.17, reflecting manageable leverage. The return on equity is favorable at 10.8%, suggesting effective use of equity. However, the equity ratio stands at a moderate 43.8%, implying potential leverage risks if not managed carefully.

Cash Flow

Core Laboratories has shown strong cash flow management, with a significant operating cash flow to net income ratio of 2.05, indicating robust cash generation relative to earnings. Free cash flow has also grown, supporting financial stability and operational flexibility.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	517.80M	523.85M	509.79M	489.74M	470.25M	487.27M
Gross Profit	87.57M	88.37M	94.05M	78.92M	83.84M	91.63M
EBITDA	66.80M	73.27M	70.42M	58.69M	63.78M	-56.50M
Net Income	28.03M	31.40M	36.67M	19.45M	19.73M	-97.07M
Balance Sheet
Total Assets	591.52M	590.41M	586.39M	578.35M	580.85M	568.58M
Cash, Cash Equivalents and Short-Term Investments	22.11M	19.16M	15.12M	15.43M	17.70M	13.81M
Total Debt	180.00M	180.14M	215.38M	222.39M	250.26M	326.98M
Total Liabilities	332.16M	332.67M	356.59M	389.40M	419.85M	493.01M
Stockholders Equity	253.39M	251.99M	224.81M	188.95M	161.00M	75.57M
Cash Flow
Free Cash Flow	43.90M	43.36M	14.21M	14.74M	23.04M	45.99M
Operating Cash Flow	57.43M	56.39M	24.79M	24.96M	36.58M	57.87M
Investing Cash Flow	-3.99M	-6.39M	-6.65M	-3.86M	-10.22M	7.85M
Financing Cash Flow	-46.64M	-45.96M	-18.45M	-23.38M	-22.46M	-63.01M

Core Laboratories Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 12.78
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CLB, the sentiment is Neutral. The current price of 12.78 is above the 20-day moving average (MA) of 12.03, above the 50-day MA of 11.70, and below the 200-day MA of 16.03, indicating a neutral trend. The MACD of 0.16 indicates Negative momentum. The RSI at 53.21 is Neutral, neither overbought nor oversold. The STOCH value of 80.06 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CLB.

Core Laboratories Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NESR	77 Outperform	$600.90M	7.79	1.53%	―	―	―
TTI	71 Outperform	$431.16M	4.18	55.55%	―	-4.08%	429.70%
MRC	67 Neutral	$1.09B	41.18	8.29%	―	-9.84%	-111.71%
CLB	66 Neutral	$573.38M	20.46	11.54%	0.33%	1.32%	-33.17%
PUMP	61 Neutral	$641.12M	―	-16.24%	―	-13.32%	-309.35%
OIS	59 Neutral	$335.33M	62.51	0.75%	―	-9.04%	―
Sector *	52 Neutral	C$2.90B	-1.06	-3.16%	6.06%	3.01%	-47.13%

Core Laboratories Corporate Events

Core Laboratories Shareholders Approve Key Governance Items

On May 21, 2025, Core Laboratories Inc. held its Annual Meeting of Shareholders in Houston, Texas, where all proposed items were approved. Shareholders elected one new and re-elected two Class II Directors, ratified KPMG as the independent public accountant for 2025, and approved the executive compensation policies, reflecting strong shareholder support for the company’s governance and financial strategies.

The most recent analyst rating on (CLB) stock is a Sell with a $13.00 price target. To see the full list of analyst forecasts on Core Laboratories stock, see the CLB Stock Forecast page.

Core Laboratories Reports Q1 2025 Financial Results

On April 23, 2025, Core Laboratories announced a quarterly cash dividend and reported its first quarter 2025 financial results. The company experienced a decline in revenue and operating income due to geopolitical conflicts and sanctions affecting demand for its services. Despite these challenges, Core Labs engaged new clients in the Middle East and Africa, and continued to innovate with its proprietary technologies. The company also reduced its net debt and repurchased shares, while focusing on growth opportunities in unconventional plays and geothermal projects.